Propanc Biopharma enters $25K convertible note and $13K AUD loan for working capital

Propanc Biopharma, Inc.

Issued $25,000 convertible note to Geebis Consulting at 8% interest; maturity June 2026; conversion price $5.00.
Note sold at $22,500 (10% OID); prepayment options with premiums from 110% to 125% within first 180 days.
Received $13,188 AUD loan from board member at 12% interest, maturing June 30, 2025.
Proceeds from both financings will be used for general working capital purposes.
Note is subject to 4.99% beneficial ownership limitation; conversion price adjusts on default.

item 1.01item 2.03item 3.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.